<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00563108</url>
  </required_header>
  <id_info>
    <org_study_id>UW 03-312 T312</org_study_id>
    <secondary_id>HARECCTR0500037</secondary_id>
    <nct_id>NCT00563108</nct_id>
  </id_info>
  <brief_title>Basiliximab for the Treatment of Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation</brief_title>
  <official_title>A Double-blind Randomized Single-center Trial of Basiliximab for the Treatment of Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Authority, Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Hong Kong Blood Cancer Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Authority, Hong Kong</source>
  <brief_summary>
    <textblock>
      Graft-versus-host disease (GVHD) contributes substantially to transplant-related morbidity
      and mortality. Steroids remains first line therapy for acute GVHD but there is currently no
      consensus on second line therapy for those in whom steroids have been ineffective.
      Basiliximab has been shown to be a safe and effective immunosuppresant in the prevention and
      treatment of rejection after renal transplantation and its role in acute GVHD prophylaxis and
      treatment has been described favourably. This is a randomized control trial to investigate
      its efficacy and safety in the management of acute GVHD post allogeneic stem cell
      transplantation (SCT).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2004</start_date>
  <completion_date type="Anticipated">December 2008</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resolution of GVHD by Day 12</measure>
    <time_frame>12 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration and grading of acute GVHD</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total dose of steroid and immunosuppresant</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality, GVHD-related and all cause</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Graft vs Host Disease</condition>
  <condition>Hematopoietic Stem Cell Transplantation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Basiliximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Grade II to IV acute GVHD after SCT

        Exclusion Criteria:

          -  Known allergy to basilixmab
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Lawrence SY Ma, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medicine/ Haematology and Oncology, Queen Mary Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Winnie WW Cheung, Dr</last_name>
    <phone>(852) 2855 3111</phone>
    <email>cheungww@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>AYH Leung, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Tse, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>YL Kwong, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raymond Liang, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>AKW Lie, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>WY Au, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.ekg.org.hk/HAREC-CTR/RegistryDisplay2.jsp?HARECID=HARECCTR0500037</url>
    <description>HAREC Clinical Trial Registry</description>
  </link>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2007</study_first_submitted>
  <study_first_submitted_qc>November 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2007</study_first_posted>
  <last_update_submitted>July 6, 2010</last_update_submitted>
  <last_update_submitted_qc>July 6, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 7, 2010</last_update_posted>
  <keyword>Acute graft-versus-host disease post allogeneic stem cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Basiliximab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

